Novartis Group in Russia

Novartis Group in Russia

Novartis Group in Russia
Official website:novartis.com

Novartis is an international pharmaceutical company headquartered in Basel, Switzerland. Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 thousand people of more than 140 nationalities work at Novartis around the world, company products are available in 155 countries.

Novartis Group in Russia offers healthcare solutions that meet the most urgent needs of society and patients. The history of the company has been conducted since the opening of the first pharmaceutical manufactory at the end of the XIX century and for almost a century and a half the company has been a reliable partner of the healthcare system in our country. In 1996, Novartis opened a representative office in Russia (as the result of the merger of the representative offices of Sandoz and Ciba-Geigy companies). The company develops research and educational activities in partnership with the leading universities and research institutes, implements various programs to improve the healthcare system, and conducts international and local clinical trials.

Novartis has a diversified product portfolio and occupies leading positions in the Russian market in the production of innovative and replicated drugs. According to the Association of Clinical Trials Organizations (ACTO), the company is the leader in the number of approved international clinical studies in Russia in 2018 among the foreign manufacturers. Company's investment in clinical trials accounted to more than 58 million US dollars within 2015-2018. All Group’s divisions are currently presented in Russia - innovative products, generic pharmaceutical and biosimilars, own manufacturing site production in St. Petersburg - while the number of employees approaches 2,000.